Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy
Author:
Affiliation:
1. Department of Radiation Oncology; Memorial Sloan-Kettering Cancer Center; New York New York
2. Department of Epidemiology and Biostatistics; Memorial Sloan-Kettering Cancer Center; New York New York
Publisher
Wiley
Subject
Urology,Oncology
Reference33 articles.
1. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010
2. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013
3. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08);Templeton;Eur Urol,2013
4. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain;Pao;PLoS Med,2005
5. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers;Diaz;Nature,2012
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance;JCO Precision Oncology;2024-04
2. Outcomes in patients with high- and very high-risk localized prostate cancer treated with definitive IMRT and long-term hormone therapy;Japanese Journal of Clinical Oncology;2023-12-23
3. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer;ESMO Open;2022-06
4. Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer;Clinical Pharmacology & Therapeutics;2022-04-12
5. Increased risk of disease progression in younger men: Analysis of factors predicting biochemical failure and castration-resistant prostate cancer after high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer;Urologic Oncology: Seminars and Original Investigations;2021-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3